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Purpose: High-mobility group box 1 protein (HMGB1) has been reported to be a potent proangiogenic factor induced by
inflammatory stress. In this study, we explore the role of HMGB1 in advanced glycation end products (AGEs)–induced
vascular endothelial growth factor A (VEGF-A) production in rat retinal ganglion cell line 5 (RGC-5) cells.
Methods: The VEGF-A protein and mRNA levels in conditioned medium of RGC-5 cells incubated with AGE-modified
BSA (AGE-BSA) were examined with real-time PCR and enzyme-linked immunosorbent assay (ELISA), and BSA-
treated cells were used as controls. The expression of HMGB1, c-Jun N-terminal kinase (JNK), extracellular-signal-
regulated kinase (ERK), and p38 mitogen-activated protein kinase (p38 MAPK) was assessed with immunofluorescence
and western blot analysis. Reactive oxidative species (ROS) were detected with flow cytometry measurements of peroxide-
dependent oxidation of 2′-7′-dichlorofluorescein-diacetate (DCFH-DA). N-Acetyl-L-cysteine (NAC), glycyrrhizin (GZ),
and SP600125 were used to block ROS, HMGB1, and JNK, respectively.
Results: Compared with the BSA controls, the RGC-5 cells incubated with AGE-BSA showed a dose- and time-dependent
increase in VEGF-A mRNA and VEGF-A protein secretion in the supernatant, with the highest levels achieved at 24 h.
AGE-BSA stimulated a significant release of HMGB1 in the supernatant and a significant increase of intracellular ROS
production at 3 h. NAC blocked HMGB1 production in a dose-dependent manner. Blocking with GZ, NAC, and JNK
significantly suppressed AGE-induced VEGF-A production.
Conclusions: HMGB1 is implicated in the production of VEGF-A in retinal ganglion cell line-5 (RGC-5). Blocking
HMGB1, ROS, or the JNK pathway may attenuate VEGF-A production, suggesting HMGB1 and related signaling
molecules play a role in diabetic retinopathy.
Diabetic retinopathy is one of the leading causes of vision
loss in patients under 65 years of age [1]. Diabetes causes
retinal microvasculopathy associated with pericyte cell death,
microaneurysms,  abnormal  vascular  permeability,  and
macular  edema.  Long-term  microvasculopathy  results  in
retinal  hypoxia  and  subsequent  neovascularization  with
abnormal blood vessels proliferating into the vitreal cavity
[2,3].
Glycation,  the  result  of  a  protein  or  lipid  molecule
bonding with sugar molecules, is a consequence of the aging
process. The results of a chain of chemical reactions after the
initiation  of  glycation  are  now  referred  to  as  advanced
glycation end products (AGEs), which can contribute to the
accelerated  micro-  and  macrovasculopathy  observed  in
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diabetes [4]. AGEs induce vascular endothelial growth factor
A  (VEGF-A)  production  via  the  receptor  for  advanced
glycation  end  products  (RAGE)  and  activation  of
nicotinamide  adenine  dinucleotide  phosphate  (NADPH)
oxidase or protein kinase C (PKC)-alpha in mesangial cells
[5]. In addition to AGEs, high-mobility group box protein 1
(HMGB1) is another ligand of RAGE [6]. HMGB1 is present
in the nucleus of all mammalian cells, where this protein
induces  structural  and  transcriptional  activities  under
physiologic  conditions  [7-9].  However,  HMGB1  is  also
implicated  as  an  important  endogenous  danger  signaling
molecule and amplifies the activities of immunostimulatory
molecules in a synergistic manner [10,11].
Presently, the clinical treatment for diabetic retinopathy
is limited to pan-retinal photocoagulation and vitrectomy for
late  proliferative  disease  and  anti-VEGF  therapy  for
controlling macular edema that impairs vision. Identifying
new  strategies  for  treatment  before  the  late  stage  of
retinopathy is desirable. HMGB1 has been identified as a
potent proangiogenic stimulus in experimental studies [12,
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83813],  and  its  roles  in  various  retinal  diseases  are  being
elucidated [14-18]. In this study, we investigate the role of
HMGB1 in retinal ganglion cell line 5 (RGC-5) cells, a source
of  retinal  VEGF-A  [19,20].  We  expect  our  findings  will
provide clues for future management of diabetic retinopathy.
METHODS
Chemical and instrument suppliers: Dulbecco’s phosphate
buffered saline (DPBS) was purchased from Hyclone (Logan,
IL). Dulbecco’s modified Eagle’s medium (DMEM) and fetal
bovine serum (FBS) were from Invitrogen-GIBCO (Carlsbad,
CA). Kits for RNA extraction were from Qiagen (Venlo, the
Netherlands). Primers for quantitative real-time PCR were
from Genomics (Taipei, Taiwan). Protein extraction buffer
was  from  GE  Healthcare  (Little  Chalfont,  UK).  The
Subcellular  fraction  extraction  kit  S-PEK  was  from
Merck4Bioscences (Darmstadt, Germany). The BCA Protein
Assay Kit was from Thermo Scientific (Waltham, MA). ECL
western  blotting  detection  reagents  and  polyvinylidene
fluoride membrane were from Millipore (Billerica, MA). The
Rat VEGF-A enzyme-linked immunosorbent assay (ELISA)
assay kit was from Peprotech (Rocky Hill, NJ). The Cell
Proliferation Kit II (XTT) and the Cytotoxicity Detection Kit
(LDH)  were  from  Roche  (Penzburg,  Germany).  Anti-p38
(rabbit  polyclonal)  and  anti-glyceraldehyde  3-phosphate
dehydrogenase  (GAPDH;  mouse  monoclonal)  were  from
Abcam (Cambridge, UK). Anti-HMGB1 (rabbit monoclonal),
antibeta  tubulin  (rabbit  monoclonal),  anti-phospho-p38
(rabbit monoclonal), and anti-JNK2 (rabbit monoclonal) were
from  Epitomics  (Burlingame,  CA).  Anti-phospho-ERK
(rabbit  monoclonal),  anti-ERK,  and  anti-phospho-JNK
(mouse  monoclonal)  were  from  Cell  Signaling  (Beverly,
MA).  Anti-RAGE  (rabbit  polyclonal)  and  anti-Toll-like
receptor 4 (anti-TLR4; mouse monoclonal) were from Santa
Cruz Biotechnology (Santa Cruz, CA). Alexa Fluor 488 and
594 conjugated secondary antibodies and 4',6-diamidino-2-
phenylindole (DAPI) were from Invitrogen (Carlsbad, CA).
Mitogen-activated  protein  kinase  (MAPK)  inhibitors
including SB230580, SP600125, PD98059, and U0126 were
from  Cayman  (Ann  Arbor,  MI).  N-Acetyl-L-cysteine  and
glycyrrhizin (GZ) were from Sigma-Aldrich (St. Louis, MO).
AGE-BSA and BSA for controlled experiments were from
Biovision  (Mountain  View,  CA).  The  Sunrise  microplate
reader  for  ELISA  was  from  TECAN  (Männedorf,
Switzerland).  Flow  cytometry  was  performed  with
FACSCalibur (BD Biosciences, Franklin Lakes, NJ). ECL
western blotting analysis was performed with the Molecular
Imager  Versadoc  MP4000  from  Bio-Rad  (Hercules,  CA).
Real-time  PCR  analysis  was  performed  with  the
LightCycler®  480  Real-Time  PCR  System  from  Roche
(Penzburg, Germany). The fluorescence microscope Eclipse
800 was from Nikon (Tokyo, Japan).
Cell  culture  and  treatment  with  advanced  glycation  end
products or inhibitors of high-mobility box 1 protein and
mitogen-activated protein kinase signaling pathways: RGC-5
(courtesy of Dr. Chi-Chun Lai) was obtained from Dr. Neeraj
Agarwal, North Texas Health Science Center, Fort Worth,
TX. The cell stained positively with anti-neurofilament-M
(NF-M) antibody (Cell signaling, Beverly, MA). RGC-5 cells
were cultured in DMEM with low glucose and 10% FBS and
1% penicillin/streptomycin mixture at 37 °C in a humidified
atmosphere of 5% of CO2. For most experiments, 2.5×106
cells were plated in 60-mm dishes (430166; Corning, Lowell,
MA). For ELISA assays, 2×104 cells were plated on a 96-well
plate  (167008;  Nunc,  Roskilde,  Denmark).  For
immunofluorescence studies, 2.5×105 cells were seeded on a
coverslip and mounted on a 24-well plate (142475; Nunc).
After sub-confluent cell growth, the medium was replaced by
DMEM with 0.5% FBS for 4 h before treatment with AGE-
BSA (Biovision). AGE-BSA (200 μg/ml) was added to the
culture  medium  for  specific  time  intervals  for  individual
experiments,  and  cells  treated  with  BSA  (200  μg/ml;
Biovision) were used as controls. To study the effects of
blocking HMGB1 with glycyrrhizin (GZ), or blocking the
MAPK pathway with specific MAPK inhibitors (Cayman),
including SB230580, SP600125, PD98059, or U0126, the
individual inhibitor was premixed in the medium for 1 h
before AGE-BSA was added.
Protein  collection:  After  treatment,  the  protein  in  the
supernatant  was  collected  using  previously  described
protocols  [21].  Briefly,  cell-conditioned  medium  was
centrifuged at 250× g for 10 min at 4 °C to separate detached
cells and then harvested carefully and filtered through Millex-
GP (Millipore) to remove cell debris and macromolecular
complexes. Samples were then concentrated with Amicon
Ultra–10,000  NMWL  (Millipore)  according  to  the
manufacturer’s instructions. After the protein was quantified
with the BCA kit, an equal amount of protein derived from
the supernatant was loaded for western blot analysis.
Cell viability assays: The effect of AGE-BSA or BSA on
RGC-5 cell viability was measured with a cell proliferation
kit  (XTT),  and  cytotoxicity  was  assessed  using  a  lactate
dehydrogenase (LDH) activity assay kit. Cells (2×104) were
seeded on a 96-well flat bottom plate (167008; Nunc). After
24-h incubation with either AGE-BSA or BSA, cells were
treated with reagents for the XTT assay according to the
manufacturer’s instructions (Roche). The percentage of viable
cells was compared to that of sterile DPBS-treated cells. To
assess the cytotoxic effect of AGE-BSA on RGC-5 cells, we
used an LDH assay kit and followed the protocol provided by
the manufacturer (Roche). Cells treated with the lysis solution
were  considered  100%  damaged  and  used  as  a  positive
control. The results of both assays were determined based on
optical density detected with an ELISA reader (TECAN). The
statistical analysis was based on the results of six independent
experiments.
Western blotting for whole cell and fractionated subcellular
proteins: After treatment, whole-cell lysates of RGC-5 cells
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839were obtained by washing with cold DPBS and lysed using
protein extraction buffer (28–9412–79; GE Healthcare) with
a  protease  inhibitor  (Sigma-Aldrich).  When  subcellular
fractionation  of  protein  was  required,  proteins  from  the
cytosol  and  nucleus  were  prepared  using  S-PEK  (Merck
Biosciences)  according  to  the  manufacturer’s  instruction
[22]. Proteins derived from subcellular fractions, total cell
lysates, or concentrated cell culture supernatant were resolved
with sodium dodecyl sulfate–PAGE (4% stacking and 10%
resolving gel) and transferred onto a polyvinylidene fluoride
membrane  (Millipore).  Membranes  were  blocked  with
SuperBlock blocking buffer (Thermo Scientific). Blots were
probed overnight at 4 °C with 1:200 to 1:2,000 of diluted
primary antibodies specific for the individual target protein,
and  then  incubated  with  1:5,000  diluted  horseradish
peroxidase–linked  secondary  antibodies  (Jackson
ImmunoResearch, West Grove, PA). Images were captured
with the ECL imaging system (Bio-Rad). Statistical analysis
was based on the results of four independent experiments.
RNA expression analysis with real-time polymerase chain
reaction:  Total  RNA  was  extracted  from  cells  using  the
RNeasy Mini Kit (Qiagen). After quantification, total RNA
(1 μg) was used to synthesize cDNA by reverse transcription
with oligo(dT)15 primer, Moloney Murine Leukemia Virus
reverse  transcriptase,  and  deoxynucleoside  triphosphate
mixture  (Promega,  Madison,  WI)  according  to  the
manufacturer’s  recommendations.  Quantitative  real-time
PCR (qPCR) was performed with the Light-Cycler Real-Time
PCR System (Roche) to study the expression of VEGF-A
using SYBR green assays. The sequences of the forward and
reverse primers of VEGF-A were 5′-CAG CTA TTG CCG
TCC AAT TGA-3′ and 5′-CCA GGG CTT CAT CAT TGC
A-3′,  respectively  [23].  The  expression  levels  of  β-actin
(Actb) were used as controls (forward primer, 5′-AGG CCC
CTC TGA AAC CTA AG-3′, and reverse primer, 5′-CAA
CAC AGC CTG GAT GGC TAC-3′). Analysis was based on
the results of three independent experiments.
Enzyme-linked immunosorbent assay for vascular endothelial
growth factor A: After subconfluent growth, RGC-5 cells
were starved from serum for 4 h and stimulated by 24-h
incubation  with  fresh  media  containing  different
concentrations of AGE-BSA (0, 100, 200, 500, and 1,000 μg/
ml).  The  VEGF-A  released  into  the  culture  medium  was
collected and quantified after treatment with AGE-BSA with
or without specific inhibitors. The results were compared with
those of the control BSA at equal concentrations according to
the  instruction  provided  by  the  manufacturer  (Peprotech).
Plates  were  read  at  450  nm  using  a  microplate
spectrophotometer  (TECAN).  Analysis  was  based  on  the
results of eight independent experiments.
Reactive oxidative species measurement: Intracellular ROS
formation after treatment of the RGC-5 cells with AGEs was
evaluated  using  peroxide-dependent  oxidation  of  2′-7′-
dichlorofluorescein-diacetate  (DCFH-DA).  DCFH-DA  is
cleaved  intracellularly  by  nonspecific  esterases  to  form
DCFH,  which  is  further  oxidized  by  ROS  to  form  the
fluorescent  compound  DCF.  DCFH-DA  (Sigma-Aldrich)
working solution was added directly to the medium to attain
a concentration of 2 μM; and then incubated for 30 min at
37  °C.  Cells  were  harvested  and  then  washed  once,
resuspended in DPBS, and kept on ice for immediate detection
with  flow  cytometry  (FACSCalibur;  BD  Biosciences).
Analysis  was  based  on  the  results  of  three  independent
experiments.
Immunofluorescence analysis of RGC-5 cells after treatment
with  advanced  glycation  end  products–BSA:  Cells  were
seeded and cultured on glass coverslips precoated with 0.01%
poly-L-lysine (Sigma-Aldrich) for 1 h. After the cells were
treated with AGE-BSA for 24 h, they were fixed with 4%
paraformaldehyde for 30 min and then treated with 0.1%
Triton X-100 for 10 min at room temperature. Blocking was
achieved with PBS containing 5% normal goat serum for 1 h
at room temperature. Cells were then incubated with an anti-
HMGB1 antibody overnight at 4 °C, followed by incubation
with Alexa Fluor 594 conjugated secondary antibody and
DAPI for nuclear staining. Coverslips were mounted on slides
using  fluorescence  mounting  medium  (Dako,  Glostrup,
Denmark).  Fluorescence  image  capture  and  analysis  were
performed with a fluorescence microscope (Nikon).
Statistical analysis: Data are shown as means±SD or as a
percentage.  The  Statistical  Package  for  Social  Science
program (SPSS for Windows, version 13.0; SPSS, Chicago,
IL) was used for statistical analysis. A one-way ANOVA was
used  for  comparing  the  differences  between  groups.  The
Mann–Whitney U test was used when normal distribution of
results was not observed, and p values less than 0.05 were
considered statistically significant.
RESULTS
Advanced glycation end products induce vascular endothelial
growth factor-A expression and release in culture media in
RGC-5 cells: The VEGF-A protein secreted into the culture
media  was  quantified  using  a  VEGF-A  ELISA  kit
(Peprotech). A dose-dependent increase in VEGF-A in the
media  was  found  in  RGC-5  cells  treated  for  24  h  with
increasing  concentration  of  AGE-BSA  (from  100  to
1,000 μg/ml), when compared with the VEGF-A level in the
BSA control (130.0±65.3 versus 105.2±42.0 pg/ml at 100 μg/
ml,  178.4±35.4  versus  105.0±14.4  pg/ml  at  200  μg/ml,
171.7±37.9  versus  101.0±32.4  pg/ml  at  500  μg/ml,  and
195.4±44.9  versus  97.1±45.5  pg/ml  at  1,000  μg/ml,
respectively; one-way ANOVA with post hoc Bonferroni test,
p=1.000, p=0.014, p=0.035, and p=0.025, respectively, Figure
1A).  Elevation  of  VEGF-A  mRNA  levels  in  RGC-5  cells
started 12 h after incubation with AGE-BSA (200 μg/ml) and
reached 4.33±0.54 fold expression over baseline values at 24
Molecular Vision 2012; 18:838-850 <http://www.molvis.org/molvis/v18/a89> © 2012 Molecular Vision
840Figure  1.  Advanced  glycation  end
products–BSA  (AGE-BSA)  treatment
results in vascular endothelial growth
factor (VEGF)-A upregulation in retinal
ganglion  cell  (RGC)-5  cells.  A:  The
VEGF-A concentration in the media of
RGC-5 cells treated with 100 to 1,000
μg/ml  of  AGE-BSA  for  24  h  was
detected  with  enzyme-linked
immunosorbent assay (ELISA). (n=8, *
p<0.05, between AGE-BSA and BSA
control). B: The change in the VEGF-A
mRNA  levels  of  RGC-5  cell  was
detected  with  real-time  qPCR  after
incubation with AGE-BSA (200 μg/ml)
for  12  to  24  h  (n=3).  C:  VEGF-A
concentration  in  conditioned  media
increased over time after incubation of
RGC-5 cells with 200 μg/ml of AGE-
BSA (n=8).
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841h (p<0.001, Figure 1B). A time-dependent increase in VEGF-
A concentration was detected in the medium after treatment
of RGC-5 cells with AGE-BSA for 12, 24, and 36 h (p=0.002,
p<0.001, and p<0.001, respectively, Figure 1C).
Figure  2.  The  distribution  of  high-
mobility group box protein 1 (HMGB1)
in retinal ganglion cell (RGC)-5 cells
changed  following  treatment  with
advanced glycation end products–BSA
(AGE-BSA).  A:  Immunofluorescence
photographs (400× magnification) show
that HMGB1 appears in the cytoplasm
(arrow)  of  RGC-5  cells  at  3  h  after
treatment with 200 μg/ml of AGE-BSA,
while HMGB1 remains in the nucleus of
RGC-5  cells  treated  with  either  BSA
(200 μg/ml) or PBS. The left column
shows  the  distribution  of  HMGB1
protein  with  green  fluorescence.  The
central  column  shows  the  nucleus
stained  with  4',6-diamidino-2-
phenylindole (DAPI; blue), and the right
column  shows  merged  pictures.  B:
Subcellular  fractionation  of  proteins
shows a significant increase of HMGB1
levels in the cytosol of RGC-5 cells after
incubation with AGE-BSA for 3 h (n=4,
p<0.05, BSA-treated cells were used as
control). The level of HMGB1 in the
nucleus  was  not  different  between
groups over time.
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842Advanced glycation end products induce translocation and
release of high-mobility box 1 protein from RGC-5 cells:
Immunofluorescence  studies  demonstrated  that  HMGB1
appeared in the cytoplasm after 3 h of incubation with AGE-
BSA. Meanwhile, HMGB1 remained localized in the nucleus
in  control  RGC-5  cells  treated  with  BSA  or  DPBS  only
(Figure 2A). Significant increases in cytosolic HMGB1 in
RGC-5 cells were detected with 3 h of AGE-BSA (200 μg/ml)
when compared with the BSA treatment. Nuclear HMGB1
levels remained relatively the same during 3 to 12 h of AGE-
BSA treatment. Western blot analysis of intracellular protein
of  RGC-5  showed  that  AGE-BSA  induced  a  significant
change in the cytosolic HMGB1 by 173.7%±27.6% at 3 h
(p=0.029),  which  then  decreased  to  81.0%±14.6%  at  6  h
(p=0.686)  and  105.3%±20.7%  at  12  h  (p=0.343)  when
compared  with  the  BSA-treated  cells.  AGE-BSA  caused
insignificant changes in nuclear HMGB1 by 83.3%±15.1%,
97.1±24.0%,  and  96.8%±14.1%  (p=0.275,  p=0.827,  and
p=0.827, respectively) at 3, 6, and 12 h, comparing to BSA-
treated cells (Figure 2B). Western blot analysis showed a
significant  increase  in  HMGB1  in  the  culture  medium  of
RGC-5 cells incubated with AGE-BSA for 3 h (p<0.005) but
not at any other time points (Figure 3A). The viability of the
RGC-5 cells assayed with the XTT test and the cytotoxicity
assessed with LDH showed no significant difference between
the AGE-BSA treated and control groups (Figure 3B,C).
The expressions of RAGE and TLR4 were also assessed
with western blot analysis. The RAGE protein levels at 12,
18, and 24 h compare to the baseline in AGE-BSA (200 μg/
ml) treated RGC-5 cells were 98.6%±12.5%, 107.4%±2.7%,
and 112.1%±9.4%, respectively, and 96.8%±12.6%, 101.9%
±15.6%, and 101.3%±6.3%, respectively, in the BSA-treated
cells (Figure 3D). The difference between treatments was not
significant (p=0.699, p=0.413, and p=0.114 for 12, 18, and 24
h, respectively). The TLR4 protein levels at 12, 18, and 24 h
compared to the baseline in the RGC-5 cells treated with
AGE-BSA  (200  μg/ml)  were  104.5%±14.4%,  113.6%
±14.1%,  and  132.6%±19.0%,  respectively,  and  101.1%
±17.0%, 93.4%±20.4%, and 94.6%±15.4%, respectively, in
the BSA-treated cells (Figure 3E). A significant increase in
the TLR4 protein was detected at 24 h after the AGE-BSA
treatment (p=0.931, p=0.111, and p=0.010 for 12, 18, and 24
h, respectively).
Reactive oxidative species generation in RGC-5 cells treated
with advanced glycation end products and the reverse of high-
mobility box 1 protein secretion with antioxidant N-acetyl-L-
cysteine: ROS production in the RGC-5 cells treated with
AGE-BSA  was  evaluated  using  a  peroxide-dependent
oxidation of DCFH-DA. A significant increase in ROS from
baseline  was  observed  in  the  RGC-5  cells  at  3  h  after
incubation with AGE-BSA, compared with the BSA control
(249.1%±38.4% and 153.9%±7.0%, respectively, p=0.002,
Figure  3.  Advanced  glycation  end
products–BSA  (AGE-BSA)  treatment
results in the release of high-mobility
group  box  protein  1  (HMGB1)  from
retinal ganglion cell (RGC)-5 cells. A:
HMGB1  in  the  culture  media  after
treatment of RGC-5 cells with 200 μg/
ml  of  AGE-BSA  or  BSA  alone  was
detected by western blot analysis. The
release  of  HMGB1  into  the  media
reached  significance  at  3  h  after
treatment with AGE-BSA, compared to
the  BSA  control  (n=4,  *  p<0.05;
A.U.represents arbitrary unit). B: XTT
test  and  (C)  lactate  dehydrogenase
(LDH) assay conducted after incubation
of RGC-5 cells with 200 μg/ml of AGE-
BSA  or  BSA  alone  for  24  h.  No
significant  difference  was  found
between groups (n=6, p=0.515 for XTT
and  p=0.916  for  the  LDH  test).  D:
RAGE  and  (E)  TLR4  protein  levels
were assayed with western blot analysis.
The levels of RAGE in the RGC-5 were
not different between groups over time.
However, a mild but significant increase
in the TLR4 protein was detected after
AGE-BSA  treatment  at  24  h  (n=5,
p=0.010).
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843Figure 4 A,B). Pretreatment of RGC-5 cells with 1, 5, and
10  mM  NAC,  a  known  antioxidant  [24,25],  significantly
suppressed  the  elevation  of  HMGB1  in  a  dose-dependent
manner (p=0.215, p=0.004, and p<0.001, respectively, Figure
4C).
c-Jun N-terminal kinase phosphorylation is induced in RGC-5
cells treated with advanced glycation end products and is
blocked by a high-mobility box 1 protein inhibitor: HMGB1
and RAGE activate MAPK signaling pathways [26-28]. In the
present  study,  we  focused  on  activation  of  MAPKs  by
HMGB1 in RGC-5 cells incubated with AGE-BSA or BSA
for 1.5 to 4.5 h. The results showed that only phosphorylated
JNK2/3,  but  not  phosphorylated  p38,  ERK,  or  JNK1,
increased significantly at 3 h after treatment with AGE-BSA
(Figure  5A).  The  timing  of  the  JNK2/3  activation  was
consistent  with  the  release  of  HMGB1  from  AGE-BSA–
treated RGC-5 cells in the supernatant. GZ (100 μM), which
binds and inhibits the cytokine activities of HMGB1 [29,30],
SP600125 (10 μM), and NAC (10 mM), successfully blocked
the increase of phosphorylated JNK2/3 in RGC-5 cells treated
with  AGE-BSA  for  3  h  (Figure  5B).  Treatment  with  GZ
(100 μM), NAC (5 mM), and NAC (10 mM) for 24 h showed
insignificant changes in RGC-5 cell viability on the XTT,
which  were  94.6%±5.4%,  97.9%±1.1%,  and  98.8%±0.7%
relative  to  control  (sterile  PBS;  p=0.134,  p=1.000,  and
p=1.000, respectively, Figure 5C).
Advanced  glycation  end  products  induced  vascular
endothelial growth factor-A upregulation is high-mobility box
1 protein dependent and works through the c-Jun N-terminal
kinase pathway: We used the HMGB1 inhibitor GZ to block
HMGB1 and found a dose-dependent decrease in VEGF-A
concentration in the culture media at 24 h after the RGC-5
cells were treated with AGE-BSA. GZ doses of 50, 100, and
200  μM  suppressed  VEGF-A  concentration  elevation  by
38.0%±77.6%,  67.2%±28.1%,  and  79.8%±30.0%,
respectively (p=0.831, p=0.021, and p=0.006, respectively,
Figure 6A). However, NAC at doses of 5 and 10 mM also
inhibited VEGF-A concentration elevation by 79.0%±18.6%,
and  94.1%±11.2%,  respectively  (p<0.001  and  p<0.001,
respectively, Figure 6B). Furthermore, specific inhibitors of
MAPK signaling pathways, namely, SP600125 (10 μM) for
JNK, SB230580 (5 μM) for p38, PD98059 (10 μM), and
U0126  (10  μM)  for  ERK,  were  studied.  Pretreatment  of
RGC-5 cells with these inhibitors before AGE-BSA treatment
resulted  in  a  decrease  in  VEGF-A  concentration  in  the
supernatant by 15.8%±72.6%, 95.2%±26.9%, −0.2%±89.1%,
and −9.8%±74.8%, respectively (p=1.000, p=0.015, p=1.000,
and  p=1.000,  respectively).  The  results  showed  that  only
SP600125, the specific inhibitor of the JNK pathway, could
inhibit the increase of VEGF-A at 24 h after incubation with
AGE-BSA (Figure 6C).
DISCUSSION
Previous studies have confirmed the effects of AGEs on the
pathogenesis  of  a  variety  of  diseases,  including  retinal
microangiopathy  [31-35].  In  this  study,  we  confirmed  a
unique role played by HMGB1 in AGE-BSA-induced VEGF-
A secretion from RGC-5 cells. Our results are consistent with
recent studies that showed that HMGB1 provides a strong
proangiogenic stimulus both in vitro and in vivo [12,13]. It
has been demonstrated that
HMGB1 stimulates membrane ruffling and repair of a
mechanically  wounded  endothelial  cell  monolayer,  causes
endothelial cell sprouting, and stimulates neovascularization
of  chicken  embryo  chorioallantoic  membrane  via  RAGE
[12]. The crucial role of HMGB1 has also been demonstrated
in diabetic mice for ischemia-induced angiogenesis through a
VEGF-dependent mechanism [13].
VEGF-A has been recognized as a critical mediator of
diabetic  retinopathy  in  experimental  and  clinical  studies
[34-36]. However, the modulation of VEGF-A in the retina of
diabetic patients before the stage of proliferative retinopathy
with  neovascularization  is  not  completely  clear.  We  have
demonstrated  that  HMGB1  might  play  a  role  in  the
upregulation  of  VEGF-A  in  retinal  ganglion  cells  after
exposure  to  AGEs.  Binding  of  glycyrrhizin  to
HMGB1inhibits  the  phosphorylation  and  physiologic
activities of HMGB1 in vitro [29]. Glycyrrhizin has also been
reported  to  inhibit  the  chemoattractant  and  mitogenic
activities of HMGB1, and only has a weak inhibitory effect
on its intranuclear DNA-binding function [30]. In our study,
blocking  HMGB1  with  glycyrrhizin  successfully  inhibits
AGE-BSA-induced upregulation of VEGF-A.
Blocking  HMGB1  suppressed  the  AGEs-induced
upregulation of VEGF-A in our study. We deduce that the
extracellular  HMGB1  protein  works  as  a  cytokine  or  a
cofactor that amplifies the effect of the AGE-RAGE axis, in
an autocrine/paracrine manner, and mediates the secretion of
survival  factors  including  VEGF-A  for  counteracting  the
oxidative stress. Glycyrrhizin used in our study suppressed
38.0%  to  79.8%  of  VEGF-A  upregulation  in  response  to
AGEs, instead of totally suppressing it; therefore, a reduced
level of VEGF-A upregulation and secretion from RGC-5
cells was induced by AGEs without augmentation of HMGB1.
Another possible explanation for the effect of glycyrrhizin on
suppression of VEGF-A upregulation is the other signaling
pathway triggered by HMGB1 outside the AGE-RAGE axis.
In  our  study,  an  increase  in  the  TLR4  protein  level  was
detected in RGC-5 cells treated by AGEs for 24 h. HMGB1
can  form  highly  inflammatory  complexes  with  single-
stranded  DNA,  lipopolysaccharide,  interleukin-1beta,  and
nucleosomes, which interact with TLR9, TLR4, interleukin 1
receptor,  and  TLR2  receptors,  respectively  [37].  HMGB1
isolated from cells cultured in the presence of IL-1β, IFN-γ,
and TNF-α had enhanced proinflammatory activities through
binding to mediators such as IL-1β [38]. One recent study
showed that Toll-interleukin 1 receptor domain-containing
adaptor protein and MyD88, which are known to be adaptor
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844Figure  4.  Reactive  oxidative  species
(ROS) could be the trigger for release of
high-mobility  group  box  protein  1
(HMGB1)  in  retinal  ganglion  cell
(RGC)-5  cells.  A:  Flow  cytometric
histogram shows an increase in ROS at
3  h  in  RGC-5  cells  treated  with
advanced glycation end products–BSA
(AGE-BSA; red) or BSA alone (black).
B:  Histogram  shows  that  DCF
fluorescence changes with time (n=3).
C: Pretreatment of RGC-5 cells with the
antioxidant N-acetyl-L-cysteine (NAC)
reduces  the  AGE-BSA-induced
HMGB1  protein  levels  in  the
supernatant at 3 h in a dose-dependent
manner.  Abbreviations:  A,  AGEs;  B,
BSA; N1, N5, and N10: RGC-5 cells
pretreated with NAC at concentrations
of 1, 5, and 10 mM respectively (n=4).
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845proteins for TLR2 and TLR4, bound to the phosphorylated
RAGE  after  ligand  binding  and  transduced  a  signal  to
downstream molecules [39]. TLR signaling pathways have
been shown to mediate VEGF production following acute
myocardial  ischemia-reperfusion  [40],  and
lipopolysaccharide-induced  prostaglandin  (PG)I2/
prostacyclin receptor interaction in macrophage [41]. The role
of TLRs in RGC-5 cells and VEGF-A upregulation is the
direction of our future study.
HMGB1  is  released  from  neural  cells  in  response  to
stresses  such  as  chemical  ischemia,  oxidative  stress  by
hydrogen peroxide, and excitotoxicity by glutamate [42]. In
this study, HMGB1 was detected in the cytosol of RGC-5 cells
and was released into culture media within 3 h of treatment
with AGE-BSA. The cytosolic HMGB1 in RGC-5 cells could
be  the  result  of  translocation  from  nuclei.  The
immunofluorescence studies in our study showed a pattern of
cytosolic translocation, which has been reported in murine
macrophage-like  RAW  264.7  cells  treated  with  hydrogen
peroxide [43]. The release of HMGB1 is an active process
rather than a passive phenomenon from damaged nuclei or
necrotic  cells,  as  there  are  no  significant  changes  in  cell
viability and cytotoxicity in RGC-5 cells treated with AGE-
BSA. Active secretion of HMGB1 from the RGC-5 cell line
has not been demonstrated before the present study. However,
the insignificant changes in HMGB1 from nuclear fraction in
our study suggest that secretion of newly synthesized HMGB1
protein by RGC-5 may also be possible, which needs to be
clarified with further studies.
The elevation of levels of intracellular ROS following
AGE-BSA  treatment  could  be  responsible  for  triggering
active  secretion  of  HMGB1  from  RGC-5  cells.  BSA  is
commonly used as a control for evaluating the effect of AGEs
in experimental researches such as in vitro study for diabetic
nephropathy with cultured mesangial cells [5], and proximal
tubular  cell  injury  via  peroxisome  proliferator-activated
receptor-gamma activation [33]. However, the generation of
ROS is a potential drawback of using BSA for in vitro studies.
BSA in a concentration of 10 mg/ml induced endoplasmic
reticulum stress, and stimulated the production of cellular
ROS  in  renal  proximal  tubule  cells  [44].  Although  the
concentration of BSA used in our study is only 1/50 of that
used for renal proximal tubule cells, an increase of ROS was
still observed in the BSA-treated RGC-5 cells. In our study,
the AGE-BSA-induced ROS levels were significantly higher
than those of BSA alone at 3 h of treatment, indicating the
effect of advanced glycation overrode BSA itself.
Various  intracellular  signaling  pathways,  including
ERK1/2 and stress-activated protein kinase/JNK, have been
shown to be activated downstream of HMGB1 in the study for
scratch  wound  closure  of  HaCaT  keratinocyte  [27],  and
hippocampal  dysfunction  in  single-Ig-interleukin-1  related
Figure  5.  Advanced  glycation  end
products–BSA  (AGE-BSA)  treatment
induces  c-Jun  N-terminal  kinase
(JNK)2/3,  and  JNK2/3  induction  is
reversed by a high-mobility group box
protein  1  (HMGB1)  blocker.  A:  The
phosphorylations of JNK, extracellular-
signal-regulated kinase (ERK), and p38
in  mitogen-activated  protein  kinase
(MAPK) signaling in retinal ganglion
cell (RGC)-5 cells treated with 200 μg/
ml of AGE-BSA for more than 3 h were
detected by western blot analysis. Only
phospho-JNK2/3,  but  not  phospho-
ERK  or  phospho-p38,  significantly
increased  at  3  h  after  treatment  with
AGE-BSA  compared  with  the  BSA
control  (n=4).  B:  Glycyrrhizin  (100
μM), SP600125 (10 μM), and NAC (10
mM)  decreased  AGEs-induced
upregulation of phospho-JNK2/3 (n=4).
C: Treatment with GZ and NAC for 24
h showed insignificant changes relative
to  sterile  PBS  in  cell  viabilities  of
RGC-5  assayed  with  XTT  (n=6).
Abbreviations: A, AGE-BSA; B, BSA;
G50 and G100, glycyrrhizin at 50 and 100
μM; SP, SP600125; N5 and N10, NAC at
5 and 10 mM.
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846Figure  6.  Advanced  glycation  end
products–BSA  (AGE-BSA)  induced
vascular  endothelial  growth  factor
(VEGF)-A expression is modulated by
glycyrrhizin,  antioxidant  N-acetyl-L-
cysteine  (NAC),  or  specific  c-Jun  N-
terminal  kinase  (JNK)  inhibitor  in
retinal  ganglion  cell  (RGC)-5  cells.
Both  glycyrrhizin  (A)  and  NAC  (B)
significantly decreased the AGE-BSA-
induced  increase  of  VEGF-A
concentration  in  the  culture  media  of
RGC-5  cells  (n=8).  (C)  AGE-BSA-
induced  increase  of  VEGF-A
concentration  in  the  culture  media  of
RGC-5  (n=8),  was  significantly
decreased by SP600125 (a specific JNK
inhibitor), but not SB230850 (5 μM; p38
inhibitor),  as  well  as  PD98059  and
U0126  (10  μM  each;  extracellular-
signal-regulated  kinase  [ERK]
inhibitors).
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847receptor (SIGIRR)-deficient mice [28]. Interaction between
AGEs and RAGE on the cell surface may also signal via p38
and  other  MAPKs.  In  this  study,  we  found  unique
upregulation  of  phospho-JNK2/3,  but  not  phospho-p38  or
phospho-ERK1/2, at the time of HMGB1 secretion in RGC-5
cells treated with AGE-BSA. Blocking the JNK pathway with
a specific inhibitor effectively reduces AGE-BSA-induced
VEGF-A  production  by  RGC-5  cells;  this  effect  was  not
observed in blocking p38 or ERK1/2. These results suggest
preferential involvement of the JNK2/3 pathway in AGEs-
induced  VEGF-A  production;  however,  the  molecular
mechanisms underlying this phenomenon await clarification.
In  conclusion,  based  on  the  results  of  this  study,  we
propose that the HMGB1 protein plays a critical role in AGE-
BSA-induced upregulation of VEGF-A in RGC-5 cells, which
involves ROS production and the JNK signaling pathway
(Figure 7). The findings from a single cell line study may not
be  sufficient  to  explain  the  pathophysiology  of  diabetic
retinopathy involving the entire retina; however, we believe
our  results  provide  the  framework  for  future  studies
investigating the role of HMGB1 in diabetic retinopathy.
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